Developing novel vaccines to cure HIV infection

Read more
HTI immunogen: a new therapeutic vaccine against HIV
Approach

HTI immunogen: a new therapeutic vaccine against HIV

The HTI immunogen was discovered by Dr. Christian Brander, CSO of AELIX Therapeutics, and co-workers. It is based on the observation that T-cell responses to certain HIV regions are enriched in individuals with enhanced control of their HIV-infection. The HTI immunogen brings these beneficial regions together as a vaccine immunogen…

More
WHO WE ARE

Meet the team

AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.

More

Whats new?

July 20, 2023

AELIX is proud to be shortlisted by Labiotech.eu as one of the five Spanish biotech companies one should know about:

Read more

June 27, 2023

AELIX Therapeutics keeps supporting FundlaCaixa’s project Alliance for Child Vaccination to contribute to the fight to reduce premature deaths of children in the world’s most vulnerable areas and to give them hope for a better future.

Read more

March 20, 2023

Small team running a big project! We are proud to be a part of the AELIX success story that we hope will pave a path for an effective therapeutic vaccine against HIV infection.

Read more
More

Testimonials